CA1335996C
(en)
*
|
1988-02-16 |
1995-06-20 |
Susumu Takada |
2-substituted carbonylimidazo¬4,5-c|quinolines
|
US5238944A
(en)
*
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
US5736553A
(en)
*
|
1988-12-15 |
1998-04-07 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
|
IL92537A
(en)
*
|
1988-12-15 |
1994-04-12 |
Riker Laboratories Inc |
Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
|
US5756747A
(en)
*
|
1989-02-27 |
1998-05-26 |
Riker Laboratories, Inc. |
1H-imidazo 4,5-c!quinolin-4-amines
|
US4994468A
(en)
*
|
1989-03-07 |
1991-02-19 |
Kyowa Hakko Kogyo Co., Ltd. |
Imidazoquinolone derivatives
|
US4929624A
(en)
*
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
US5037986A
(en)
*
|
1989-03-23 |
1991-08-06 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
|
NZ232740A
(en)
*
|
1989-04-20 |
1992-06-25 |
Riker Laboratories Inc |
Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
|
US4988815A
(en)
*
|
1989-10-26 |
1991-01-29 |
Riker Laboratories, Inc. |
3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
|
GB8928281D0
(en)
*
|
1989-12-14 |
1990-02-21 |
Smith Kline French Lab |
Compounds
|
ATE143661T1
(de)
*
|
1990-06-01 |
1996-10-15 |
Kyowa Hakko Kogyo Kk |
Imidazonaphthyridinderivate
|
ES2071340T3
(es)
*
|
1990-10-05 |
1995-06-16 |
Minnesota Mining & Mfg |
Procedimiento para la preparacion de imidazo(4,5-c)quinolin-4-aminas.
|
US5175296A
(en)
*
|
1991-03-01 |
1992-12-29 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
|
CA2289219C
(en)
*
|
1991-03-01 |
2003-05-20 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1h-imidazo[4,5-c]quinolin-4-amines
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5268376A
(en)
*
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5266575A
(en)
*
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
IL105325A
(en)
*
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
US6608201B2
(en)
*
|
1992-08-28 |
2003-08-19 |
3M Innovative Properties Company |
Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5395937A
(en)
*
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
US5352784A
(en)
*
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
ES2149276T3
(es)
*
|
1993-07-15 |
2000-11-01 |
Minnesota Mining & Mfg |
Imidazo(4,5-c)piridin-4-aminas.
|
US5648516A
(en)
*
|
1994-07-20 |
1997-07-15 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US5644063A
(en)
*
|
1994-09-08 |
1997-07-01 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-c]pyridin-4-amine intermediates
|
US5482936A
(en)
*
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
US5741908A
(en)
*
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
US5693811A
(en)
*
|
1996-06-21 |
1997-12-02 |
Minnesota Mining And Manufacturing Company |
Process for preparing tetrahdroimidazoquinolinamines
|
DE69737935T2
(de)
|
1996-10-25 |
2008-04-03 |
Minnesota Mining And Manufacturing Co., St. Paul |
Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten
|
US5939090A
(en)
*
|
1996-12-03 |
1999-08-17 |
3M Innovative Properties Company |
Gel formulations for topical drug delivery
|
JP4101302B2
(ja)
*
|
1997-01-09 |
2008-06-18 |
テルモ株式会社 |
新規アミド誘導体および合成中間体
|
SI1512685T1
(sl)
*
|
1997-12-11 |
2006-12-31 |
Minnesota Mining & Mfg |
Imidazonaftiridini in njihova uporaba v induciranju biosinteze citokina
|
UA67760C2
(uk)
*
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
AU2002300982B2
(en)
*
|
1997-12-11 |
2004-12-02 |
Minnesota Mining And Manufacturing Company |
Imidazonaphthyridines and their use in inducing cytokine biosynthesis
|
US6312715B1
(en)
|
1998-05-01 |
2001-11-06 |
3M Innovative Properties Company |
Adhesive microsphere drug delivery composition
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
JP2000119271A
(ja)
|
1998-08-12 |
2000-04-25 |
Hokuriku Seiyaku Co Ltd |
1h―イミダゾピリジン誘導体
|
US6518280B2
(en)
*
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
EP1140091B1
(en)
*
|
1999-01-08 |
2005-09-21 |
3M Innovative Properties Company |
Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6756382B2
(en)
*
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
US6894060B2
(en)
*
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
GB0023008D0
(en)
*
|
2000-09-20 |
2000-11-01 |
Glaxo Group Ltd |
Improvements in vaccination
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
UA74593C2
(en)
*
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
AU2002232498B2
(en)
*
|
2000-12-08 |
2006-05-04 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6677348B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
UA75622C2
(en)
*
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US20060142202A1
(en)
*
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
KR100892614B1
(ko)
*
|
2001-04-17 |
2009-04-09 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
신규 아데닌 유도체
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
US6893655B2
(en)
|
2001-10-09 |
2005-05-17 |
3M Innovative Properties Co. |
Transdermal delivery devices
|
AU2002360278A1
(en)
*
|
2001-10-12 |
2003-11-11 |
Coley Pharmaceutical Gmbh |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
US20040014779A1
(en)
*
|
2001-11-16 |
2004-01-22 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and toll-like recptor pathways
|
DK1450804T3
(da)
*
|
2001-11-29 |
2009-01-05 |
3M Innovative Properties Co |
Farmaceutiske formulelringer, der omfatter et immunsvarmodificerende middel
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
*
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
MXPA04008023A
(es)
*
|
2002-02-22 |
2004-11-26 |
3M Innovative Properties Co |
Metodo para reducir y tratar inmunosupresion inducida por uvb.
|
WO2003080112A2
(en)
*
|
2002-03-19 |
2003-10-02 |
Powdermed Limited |
Imidazoquinolineamines as adjuvants in hiv dna vaccination
|
CA2484049A1
(en)
*
|
2002-03-19 |
2003-10-02 |
Powdermed Limited |
Imidazoquinoline adjuvants for vaccines
|
ES2734652T3
(es)
|
2002-04-04 |
2019-12-11 |
Zoetis Belgium S A |
Oligorribonucleótidos inmunoestimulantes que contienen G y U
|
GB0211649D0
(en)
*
|
2002-05-21 |
2002-07-03 |
Novartis Ag |
Organic compounds
|
WO2003101949A2
(en)
|
2002-05-29 |
2003-12-11 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
EP1513524A4
(en)
*
|
2002-06-07 |
2008-09-03 |
3M Innovative Properties Co |
WITH ETHER SUBSTITUTED IMIDAZOPYRIDINE
|
PL374884A1
(en)
*
|
2002-07-23 |
2005-11-14 |
Teva Gyogyszergyar Zartköruen Mukodo Reszvenytarsasag |
Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via 1h-imidazo[4,5-c]quinolin-4-phthalimide intermediates
|
IL166307A0
(en)
*
|
2002-07-26 |
2006-01-15 |
|
Preparation of 1h-imidazoÄ4,5-cÜquinolin-4-amines via novel 1h-imidazoÄ4,5-cÜquinolin-4-cyano and 1h-imidazo Ä4,5-cÜquinolin-4-cyano and 1h-imidazoÄ4,5-cÜquinolin-4-carboxamide intermediates
|
BR0313587A
(pt)
|
2002-08-15 |
2006-06-13 |
3M Innovative Properties Co |
composições imunoestimuladoras e métodos de estimulação de uma resposta imune
|
US6818650B2
(en)
*
|
2002-09-26 |
2004-11-16 |
3M Innovative Properties Company |
1H-imidazo dimers
|
TWI349671B
(en)
*
|
2002-09-27 |
2011-10-01 |
Dainippon Sumitomo Pharma Co |
Novel adenine derivative and its use
|
WO2004053452A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
JP2006513212A
(ja)
|
2002-12-20 |
2006-04-20 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリール/ヘタリール置換されたイミダゾキノリン
|
EP1578419A4
(en)
|
2002-12-30 |
2008-11-12 |
3M Innovative Properties Co |
IMMUNOSTIMULATING COMBINATIONS
|
JP2006517974A
(ja)
*
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトル様受容体8に関する方法および組成物
|
JP2006519020A
(ja)
*
|
2003-02-27 |
2006-08-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Tlr介在生物活性の選択的調節
|
US8110582B2
(en)
|
2003-03-04 |
2012-02-07 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
TW200505458A
(en)
*
|
2003-03-07 |
2005-02-16 |
3M Innovative Properties Co |
1-amino 1h-imidazoquinolines
|
EP1603476A4
(en)
*
|
2003-03-13 |
2010-01-13 |
3M Innovative Properties Co |
PROCESS FOR REMOVING TATTOO
|
US7699057B2
(en)
*
|
2003-03-13 |
2010-04-20 |
3M Innovative Properties Company |
Methods for treating skin lesions
|
JP4891066B2
(ja)
*
|
2003-03-13 |
2012-03-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
皮膚の質を改善する方法
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
CA2520124A1
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of benzazole compounds for immunopotentiation
|
JP2007500210A
(ja)
*
|
2003-04-10 |
2007-01-11 |
スリーエム イノベイティブ プロパティズ カンパニー |
金属含有微粒子担体材料を使用した免疫反応調節物質化合物の送達
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
US20050032829A1
(en)
*
|
2003-06-06 |
2005-02-10 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
WO2004110991A2
(en)
*
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
US7521459B2
(en)
*
|
2003-07-28 |
2009-04-21 |
Metabeauty Inc. |
Method for treating damaged skin
|
AU2004261987A1
(en)
*
|
2003-07-31 |
2005-02-10 |
3M Innovative Properties Company |
Compositions for encapsulation and controlled release
|
EP1651190B1
(en)
*
|
2003-08-05 |
2012-09-19 |
3M Innovative Properties Company |
Formulations containing an immune response modifier
|
US8211906B1
(en)
|
2003-08-05 |
2012-07-03 |
Scherrer Lawrence C |
Method of inhibiting growth of neoplastic cells and inhibiting infection by administering an immune enhancer drug
|
TW200524927A
(en)
|
2003-08-12 |
2005-08-01 |
3M Innovative Properties Co |
Hydroxylamine substituted imidazo-containing compounds
|
EP1653959B1
(en)
*
|
2003-08-14 |
2015-05-27 |
3M Innovative Properties Company |
Lipid-modified immune response modifiers
|
EP1660122A4
(en)
*
|
2003-08-25 |
2007-10-24 |
3M Innovative Properties Co |
IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS
|
CA2536249A1
(en)
*
|
2003-08-25 |
2005-03-10 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
RU2006105101A
(ru)
|
2003-08-27 |
2007-10-10 |
3М Инновейтив Пропертиз Компани (US) |
Арилокси и арилалкиленокси замещенные имидазохинолины
|
EP1663222A4
(en)
*
|
2003-09-02 |
2008-05-21 |
3M Innovative Properties Co |
METHODS RELATING TO THE TREATMENT OF GIANCES
|
EP1660026A4
(en)
*
|
2003-09-05 |
2008-07-16 |
3M Innovative Properties Co |
TREATMENT FOR CD5 + B CELL LYMPHOMA
|
US20050059072A1
(en)
*
|
2003-09-17 |
2005-03-17 |
3M Innovative Properties Company |
Selective modulation of TLR gene expression
|
EP1668010A2
(en)
*
|
2003-10-01 |
2006-06-14 |
Taro Pharmaceuticals U.S.A., Inc. |
Method of preparing 4-amino-1h -imidazo(4,5- c )quinolines and acid addition salts thereof
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
KR101494056B1
(ko)
*
|
2003-10-03 |
2015-02-16 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
피라졸로피리딘 및 그의 유사체
|
CN1897948A
(zh)
|
2003-10-03 |
2007-01-17 |
3M创新有限公司 |
烷氧基取代的咪唑并喹啉
|
AU2004285575A1
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
WO2005047483A2
(en)
|
2003-11-12 |
2005-05-26 |
Medical Research Council |
Renta: an hiv immunogen and uses thereof
|
US7897767B2
(en)
|
2003-11-14 |
2011-03-01 |
3M Innovative Properties Company |
Oxime substituted imidazoquinolines
|
AU2004291122A1
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
JP2007512349A
(ja)
*
|
2003-11-25 |
2007-05-17 |
スリーエム イノベイティブ プロパティズ カンパニー |
ヒドロキシルアミンおよびオキシム置換した、イミダゾキノリン、イミダゾピリジン、およびイミダゾナフチリジン
|
CA2547020C
(en)
|
2003-11-25 |
2014-03-25 |
3M Innovative Properties Company |
1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
|
EP1689361A4
(en)
*
|
2003-12-02 |
2009-06-17 |
3M Innovative Properties Co |
THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
TW200533352A
(en)
*
|
2003-12-04 |
2005-10-16 |
3M Innovative Properties Co |
Sulfone substituted imidazo ring ethers
|
JP2007517035A
(ja)
|
2003-12-29 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
|
JP2007530450A
(ja)
*
|
2003-12-29 |
2007-11-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
ピペラジン、[1,4]ジアゼパン、[1,4]ジアゾカン、および[1,5]ジアゾカン縮合イミダゾ環化合物
|
CA2551399A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
WO2005067500A2
(en)
*
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
US20050201959A1
(en)
*
|
2004-03-11 |
2005-09-15 |
Vvii Newco 2003, Inc. |
Methods and compositions for altering skin coloration
|
AU2005222995B2
(en)
*
|
2004-03-15 |
2010-08-26 |
3M Innovative Properties Company |
Immune response modifier formulations and methods
|
TW200612932A
(en)
|
2004-03-24 |
2006-05-01 |
3M Innovative Properties Co |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
CN1938307B
(zh)
|
2004-03-26 |
2010-06-16 |
大日本住友制药株式会社 |
9-取代的8-氧代腺嘌呤
|
US20070225303A1
(en)
*
|
2004-03-26 |
2007-09-27 |
Haruhisa Ogita |
8-Oxoadenine Compound
|
CA2562283A1
(en)
*
|
2004-04-09 |
2005-11-24 |
3M Innovative Properties Company |
Methods, compositions, and preparations for delivery of immune response modifiers
|
CA2564855A1
(en)
*
|
2004-04-28 |
2005-10-28 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
ES2647491T3
(es)
|
2004-05-21 |
2017-12-21 |
Novartis Vaccines And Diagnostics, Inc. |
Vectores del alfavirus para las vacunas del virus de la gripe
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
WO2006009826A1
(en)
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
AU2005283085B2
(en)
*
|
2004-06-18 |
2012-06-21 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US7897609B2
(en)
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
ITMI20041282A1
(it)
*
|
2004-06-24 |
2004-09-24 |
Dipharma Spa |
Procedimento per la preparazione di imiquimod
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
ES2384390T3
(es)
*
|
2004-09-02 |
2012-07-04 |
3M Innovative Properties Company |
Sistemas cíclicos 1-alcoxi-1H-imidazo y métodos asociados
|
WO2006029115A2
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
CA2580343A1
(en)
*
|
2004-09-14 |
2006-03-23 |
Novartis Vaccines And Diagnostics, Inc. |
Imidazoquinoline compounds
|
JP2008515928A
(ja)
*
|
2004-10-08 |
2008-05-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
Dnaワクチンのためのアジュバント
|
US8080560B2
(en)
*
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
WO2006070379A1
(en)
*
|
2004-12-27 |
2006-07-06 |
Usv Limited |
A process for preparation of 4-amino-1-isobutyl-1h-imidazo[4,5-c]-quinoline (imiquimod)
|
AU2005326708C1
(en)
|
2004-12-30 |
2012-08-30 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
ES2538498T3
(es)
|
2004-12-30 |
2015-06-22 |
Meda Ab |
Utilización de Imiquimod para el tratamiento de metástasis cutáneas provenientes de un tumor de cáncer de mama
|
ES2392647T3
(es)
|
2004-12-30 |
2012-12-12 |
3M Innovative Properties Company |
Compuestos tetracíclicos quirales que inducen la biosíntesis de interferón
|
US20080188513A1
(en)
*
|
2004-12-30 |
2008-08-07 |
Taked Pharmaceutical Company Limited |
1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
JP2008530022A
(ja)
|
2005-02-04 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
免疫反応調節物質を含む水性ゲル処方物
|
EP1877056A2
(en)
|
2005-02-09 |
2008-01-16 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
|
US20080318998A1
(en)
|
2005-02-09 |
2008-12-25 |
Coley Pharmaceutical Group, Inc. |
Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
|
CA2597587A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
AU2006216997A1
(en)
*
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
CN101180312A
(zh)
|
2005-02-18 |
2008-05-14 |
诺华疫苗和诊断公司 |
来自尿路病原性大肠杆菌的免疫原
|
SI1858920T1
(sl)
|
2005-02-18 |
2016-07-29 |
Glaxosmithkline Biologicals S.A. |
Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
|
AU2006216799A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazonaphthyridines
|
US8178677B2
(en)
|
2005-02-23 |
2012-05-15 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
CA2598656A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
US8846710B2
(en)
|
2005-02-23 |
2014-09-30 |
3M Innovative Properties Company |
Method of preferentially inducing the biosynthesis of interferon
|
AU2006223148A1
(en)
*
|
2005-03-14 |
2006-09-21 |
3M Innovative Properties Company |
Method of treating actinic keratosis
|
JP2008533189A
(ja)
*
|
2005-03-21 |
2008-08-21 |
フエルレル インターナショナル,ソシエダッド アノニマ |
1−置換1H−イミダゾ[4,5−c]キノリン−4−アミン化合物及びそれらのための中間体を製造するための方法
|
US7943610B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
US7943636B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
EP1874345B1
(en)
|
2005-04-25 |
2012-08-15 |
3M Innovative Properties Company |
Immunostimulatory compositions
|
WO2007011777A2
(en)
|
2005-07-18 |
2007-01-25 |
Novartis Ag |
Small animal model for hcv replication
|
ES2577514T3
(es)
|
2005-08-22 |
2016-07-15 |
The Regents Of The University Of California |
Antagonistas de TLR
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
BRPI0615788A2
(pt)
|
2005-09-09 |
2011-05-24 |
Coley Pharm Group Inc |
derivados de amida e carbamato de n-{2-[4-amino (etoximetil)-1h-imidazo [4,5-c] quinolin-1-il]-1,1-dimetiletil} metanossulfonamida, composição farmacêutica destes e seus usos
|
US8889154B2
(en)
|
2005-09-15 |
2014-11-18 |
Medicis Pharmaceutical Corporation |
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
|
TW200801003A
(en)
*
|
2005-09-16 |
2008-01-01 |
Astrazeneca Ab |
Novel compounds
|
EP1939202A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW COMPOUND OF ADENINE
|
WO2007034917A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規なアデニン化合物
|
EP1939198A4
(en)
|
2005-09-22 |
2012-02-15 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
US20080269240A1
(en)
|
2005-09-22 |
2008-10-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel Adenine Compound
|
TW200745114A
(en)
*
|
2005-09-22 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
WO2007034916A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
US20070081962A1
(en)
*
|
2005-10-06 |
2007-04-12 |
Amit Munshi |
Novel delivery of immune response modifiers for removal of chronic tattoos
|
US7718716B2
(en)
*
|
2005-10-14 |
2010-05-18 |
3M Innovative Properties Company |
Chromonic nanoparticles containing bioactive compounds
|
US7629027B2
(en)
*
|
2005-10-14 |
2009-12-08 |
3M Innovative Properties Company |
Method for making chromonic nanoparticles
|
EP1945247A1
(en)
|
2005-10-18 |
2008-07-23 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US20070100146A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Trevor Dzwiniel |
Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
|
US8088790B2
(en)
*
|
2005-11-04 |
2012-01-03 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
|
NZ592713A
(en)
|
2005-11-04 |
2012-12-21 |
Novartis Vaccines & Diagnostic |
Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
|
DK2368572T3
(da)
|
2005-11-04 |
2020-05-25 |
Seqirus Uk Ltd |
Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
|
PT1951299E
(pt)
|
2005-11-04 |
2012-02-28 |
Novartis Vaccines & Diagnostic |
Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
|
JP2009514850A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
|
EP2360175B1
(en)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus and Sapovirus virus-like particles (VLPs)
|
US20070128291A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Tokie Jeffrey H |
Method and Apparatus for Forming Chromonic Nanoparticles
|
US7807661B2
(en)
*
|
2005-12-08 |
2010-10-05 |
3M Innovative Properties Company |
Silver ion releasing articles and methods of manufacture
|
US7323568B2
(en)
*
|
2005-12-12 |
2008-01-29 |
Chemagis Ltd. |
Process for preparing Imiquimod
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
EP2478916B1
(en)
|
2006-01-27 |
2020-04-01 |
Seqirus UK Limited |
Influenza vaccines containing hemagglutinin and matrix proteins
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
WO2007100634A2
(en)
|
2006-02-22 |
2007-09-07 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
US8329721B2
(en)
|
2006-03-15 |
2012-12-11 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
|
WO2007106852A2
(en)
|
2006-03-15 |
2007-09-20 |
Coley Pharmaceutical Group, Inc. |
Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
|
EP2010537B1
(en)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
WO2007109812A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
US20100010217A1
(en)
*
|
2006-03-23 |
2010-01-14 |
Valiante Nicholas M |
Methods for the preparation of imidazole-containing compounds
|
EP2382987A1
(en)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Storage of influenza vaccines without refrigeration
|
WO2007126825A2
(en)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
CA2645832A1
(en)
*
|
2006-04-25 |
2007-11-01 |
Intercell Ag |
Hcv vaccinations
|
US20070275185A1
(en)
*
|
2006-05-23 |
2007-11-29 |
3M Innovative Properties Company |
Method of making ordered nanostructured layers
|
EP2029597A4
(en)
|
2006-05-31 |
2011-11-23 |
Univ California |
purine analogs
|
EP2029168B1
(en)
|
2006-06-02 |
2012-10-03 |
International AIDS Vaccine Initiative |
Hiv-1 clade a consensus sequences, antigens, and transgenes
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
CN101472610A
(zh)
|
2006-06-20 |
2009-07-01 |
特朗斯吉有限公司 |
重组病毒疫苗
|
EP2041135A4
(en)
*
|
2006-07-05 |
2010-12-01 |
Astrazeneca Ab |
As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK
|
US20090221703A1
(en)
|
2006-07-09 |
2009-09-03 |
Chongxi Yu |
High penetration composition and uses thereof
|
US20090238763A1
(en)
|
2006-07-09 |
2009-09-24 |
Chongxi Yu |
High penetration compositions and uses thereof
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
MX2009000507A
(es)
*
|
2006-07-14 |
2009-06-12 |
Stiefel Res Australia Pty Ltd |
Espuma farmaceutica de acidos grasos.
|
EP1889609B1
(en)
*
|
2006-07-18 |
2019-05-22 |
Meda AB |
Immune response modifier foam formulations
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
AU2007279376B2
(en)
*
|
2006-07-31 |
2012-09-06 |
Wirra Ip Pty Ltd |
Immune response modifier compositions and methods
|
EP2064230A2
(en)
|
2006-08-16 |
2009-06-03 |
Novartis AG |
Immunogens from uropathogenic escherichia coli
|
WO2008023333A2
(en)
*
|
2006-08-22 |
2008-02-28 |
Ranbaxy Laboratories Limited |
Process for the preparation of 4-(isobutylamino)-3-amino-quinoline
|
WO2008030511A2
(en)
|
2006-09-06 |
2008-03-13 |
Coley Pharmaceuticial Group, Inc. |
Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
|
AU2007297178B2
(en)
|
2006-09-11 |
2014-07-24 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
US20080103310A1
(en)
*
|
2006-10-16 |
2008-05-01 |
Janos Hajko |
Preparation of 1H-imidazo[4,5-c]quinolin-4-amines via 1H-imidazo[4, 5-c]quinolin-4-phtalimide intermediates
|
CN101553252A
(zh)
|
2006-12-06 |
2009-10-07 |
诺华有限公司 |
包含来自于四株流感病毒的抗原的疫苗
|
TW200831105A
(en)
*
|
2006-12-14 |
2008-08-01 |
Astrazeneca Ab |
Novel compounds
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
US7943771B2
(en)
*
|
2007-01-24 |
2011-05-17 |
Chemagis Ltd. |
Imiquimod production process
|
HUE031307T2
(hu)
*
|
2007-01-31 |
2017-07-28 |
Chongxi Yu |
1H-imidazo[4,5-C]kinolin-4-aminok és rokon vegyületek pozitív töltésû vízoldható prodrugjai, amelyek nagyon magas bõr-penetrációs sebességekkel rendelkeznek
|
CN106432226B
(zh)
*
|
2007-01-31 |
2019-08-30 |
于崇曦 |
1H-咪唑并[4,5-c]喹啉-4-胺类及其相关化合物的前药
|
HUE025555T2
(en)
|
2007-02-07 |
2016-02-29 |
Univ California |
Conjugates and applications of synthetic tlr agonists
|
US7659398B2
(en)
*
|
2007-02-14 |
2010-02-09 |
Chemagis Ltd. |
Imiquimod production process
|
EP1958613A1
(en)
*
|
2007-02-15 |
2008-08-20 |
Polichem S.A. |
Dermal film-forming liquid formulations for drug release to skin
|
US8067413B2
(en)
*
|
2007-03-19 |
2011-11-29 |
Astrazeneca Ab |
9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators
|
WO2008114006A1
(en)
*
|
2007-03-19 |
2008-09-25 |
Astrazeneca Ab |
9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
|
TW200902018A
(en)
*
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
WO2008118763A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Graceway Pharmaceuticals, Llc. |
Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
|
CA2679067A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Graceway Pharmaceuticals, Llc |
Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
|
WO2008118765A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Graceway Pharmaceuticals, Llc |
Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
|
CA2686163A1
(en)
*
|
2007-05-08 |
2008-11-13 |
Astrazenca Ab |
Imidazoquinolines with immuno-modulating properties
|
CA2691446C
(en)
|
2007-06-04 |
2021-07-06 |
Techfields Inc |
Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
|
NZ582595A
(en)
|
2007-06-27 |
2012-07-27 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
ES2561483T3
(es)
|
2007-09-12 |
2016-02-26 |
Glaxosmithkline Biologicals Sa |
Antígenos mutantes de GAS57 y anticuerpos de GAS57
|
PE20091236A1
(es)
|
2007-11-22 |
2009-09-16 |
Astrazeneca Ab |
Derivados de pirimidina como immunomoduladores de tlr7
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
UY31531A1
(es)
|
2007-12-17 |
2009-08-03 |
|
Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
AU2008340053A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as PI 3 kinase inhibitors
|
JP5656642B2
(ja)
|
2007-12-21 |
2015-01-21 |
ノバルティス アーゲー |
ストレプトリシンoの変異体形態
|
CN101909664A
(zh)
*
|
2008-01-15 |
2010-12-08 |
陶氏制药科学公司 |
咪喹莫特制剂
|
EA201001264A1
(ru)
*
|
2008-02-07 |
2011-04-29 |
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния |
Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
|
EA018068B1
(ru)
*
|
2008-03-03 |
2013-05-30 |
Айрм Ллк |
Соединения и композиции в качестве модуляторов активности tlr
|
AU2009227674C1
(en)
|
2008-03-18 |
2015-01-29 |
Seqirus UK Limited |
Improvements in preparation of influenza virus vaccine antigens
|
US20100160368A1
(en)
|
2008-08-18 |
2010-06-24 |
Gregory Jefferson J |
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
|
RU2630577C2
(ru)
|
2008-12-04 |
2017-09-11 |
Чунси ЮЙ |
Композиции интенсивного проникновения и их применение
|
GEP20146198B
(en)
*
|
2008-12-19 |
2014-11-25 |
Graceway Pharmaceuticals Llc |
Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
|
EP2385842A1
(en)
|
2009-01-12 |
2011-11-16 |
Novartis AG |
Cna_b domain antigens in vaccines against gram positive bacteria
|
MX2011007386A
(es)
|
2009-01-20 |
2011-08-03 |
Transgene Sa |
Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
|
WO2010088924A1
(en)
|
2009-02-06 |
2010-08-12 |
Telormedix Sa |
Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
|
JP2012517428A
(ja)
*
|
2009-02-11 |
2012-08-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Toll様レセプター調節因子および疾患の処置
|
AU2010220103A1
(en)
|
2009-03-06 |
2011-09-22 |
Novartis Ag |
Chlamydia antigens
|
SG2014014021A
(en)
|
2009-03-24 |
2014-07-30 |
Transgene Sa |
Biomarker for monitoring patients
|
PT2411521E
(pt)
|
2009-03-25 |
2015-04-21 |
Univ Texas |
Composições para estimulação de resistência imunitária inata de mamíferos contra patogénicos
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
NZ594896A
(en)
|
2009-04-17 |
2013-07-26 |
Transgene Sa |
Biomarker for monitoring patients
|
FR2949344A1
(fr)
|
2009-04-27 |
2011-03-04 |
Novartis Ag |
Vaccins de protection contre la grippe
|
GB0908772D0
(en)
*
|
2009-05-21 |
2009-07-01 |
Astrazeneca Ab |
New salts 756
|
SG175796A1
(en)
|
2009-05-21 |
2011-12-29 |
Astrazeneca Ab |
Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
SG176619A1
(en)
|
2009-07-10 |
2012-01-30 |
Transgene Sa |
Biomarker for selecting patients and related methods
|
EP2453747B1
(en)
*
|
2009-07-13 |
2017-08-30 |
Medicis Pharmaceutical Corporation |
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
|
SG178026A1
(en)
|
2009-07-15 |
2012-03-29 |
Novartis Ag |
Rsv f protein compositions and methods for making same
|
EP2837386B1
(en)
|
2009-07-16 |
2018-03-07 |
GlaxoSmithKline Biologicals SA |
Detoxified Escherichia coli immunogens
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
SG170622A1
(en)
|
2009-10-09 |
2011-05-30 |
Nitto Denko Corp |
A passive drug delivery device and a method of drug delivery
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
JP2013512859A
(ja)
*
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
EP2550362B1
(en)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
EP2558069A1
(en)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridine compositions and uses thereof
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
WO2011163617A1
(en)
|
2010-06-25 |
2011-12-29 |
Graceway Pharmaceuticals, Llc |
Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
US9072876B2
(en)
*
|
2010-08-05 |
2015-07-07 |
Medicis Pharmaceutical Corporation |
Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
|
PL2606047T3
(pl)
|
2010-08-17 |
2017-07-31 |
3M Innovative Properties Company |
Kompozycje, preparaty i sposoby obejmujące lipidowane związki modyfikujące odpowiedź immunologiczną
|
ES2575688T3
(es)
|
2010-12-16 |
2016-06-30 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
|
ES2627433T3
(es)
|
2010-12-17 |
2017-07-28 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivados de purina
|
HUE043879T2
(hu)
|
2011-01-26 |
2019-09-30 |
Glaxosmithkline Biologicals Sa |
RSV-immunizálási rend
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
EP2701736A1
(en)
|
2011-04-25 |
2014-03-05 |
Advanced Bioscience Laboratories, Inc. |
Truncated hiv envelope proteins (env), methods and compositions related thereto
|
US20140248314A1
(en)
|
2011-05-13 |
2014-09-04 |
Novartis Ag |
Pre-fusion rsv f antigens
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
EP2718292B1
(en)
|
2011-06-03 |
2018-03-14 |
3M Innovative Properties Company |
Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
|
MX347240B
(es)
|
2011-06-03 |
2017-04-20 |
3M Innovative Properties Co |
Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
|
RS57397B8
(sr)
|
2011-06-10 |
2020-01-31 |
Univ Oregon Health & Science |
Cmv glikoproteini i rekombinantni vektori
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
EP2568289A3
(en)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
WO2013040447A2
(en)
|
2011-09-14 |
2013-03-21 |
Medicis Pharmaceutical Corporation |
Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
|
WO2013041247A1
(en)
|
2011-09-23 |
2013-03-28 |
Westfällsche Wilhelms-Universitaet Muenster |
Yersinia outer protein m (yopm) in the treatment of psoriasis induced by imiquimod
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
EP2776069A1
(en)
|
2011-11-07 |
2014-09-17 |
Novartis AG |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
WO2013093629A2
(en)
|
2011-12-20 |
2013-06-27 |
Netherlands Cancer Institute |
Modular vaccines, methods and compositions related thereto
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
US9347065B2
(en)
|
2012-03-29 |
2016-05-24 |
International Aids Vaccine Initiative |
Methods to improve vector expression and genetic stability
|
WO2013162828A1
(en)
|
2012-04-27 |
2013-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
SG11201406550QA
(en)
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
AU2013261267B2
(en)
|
2012-05-18 |
2017-06-29 |
Sumitomo Pharma Co., Ltd. |
Carboxylic acid compounds
|
EP2674170B1
(en)
|
2012-06-15 |
2014-11-19 |
Invivogen |
Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
ES2637245T3
(es)
|
2012-06-29 |
2017-10-11 |
Pfizer Inc. |
Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
EP2892555B1
(en)
|
2012-09-10 |
2020-03-25 |
International Aids Vaccine Initiative |
Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
|
CN104736091A
(zh)
|
2012-09-21 |
2015-06-24 |
3M创新有限公司 |
切口保护
|
JP2015536940A
(ja)
|
2012-10-29 |
2015-12-24 |
シプラ・リミテッド |
抗ウイルス性ホスホネート類似体及びその製造方法
|
EP2730271B1
(en)
|
2012-11-11 |
2018-01-24 |
Symrise AG |
Aqeuous compositions
|
EP2732825B1
(en)
|
2012-11-19 |
2015-07-01 |
Invivogen |
Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
|
PL2941233T3
(pl)
|
2013-01-07 |
2021-03-08 |
The Trustees Of The University Of Pennsylvania |
Kompozycje i sposoby leczenia chłoniaka z komórek t typu pierwotnie skórnego
|
US9295732B2
(en)
|
2013-02-22 |
2016-03-29 |
Invivogen |
Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
|
EP2769738B1
(en)
|
2013-02-22 |
2016-07-20 |
Invivogen |
Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
|
ES2701758T3
(es)
|
2013-02-27 |
2019-02-25 |
Symrise Ag |
Extracto de jengibre para la protección de citoblastos
|
KR20150136077A
(ko)
|
2013-03-10 |
2015-12-04 |
페리테크 파마 엘티디. |
국소 조성물 및 국소 질환의 치료 방법
|
WO2014201245A1
(en)
|
2013-06-12 |
2014-12-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
|
WO2015011254A1
(en)
|
2013-07-26 |
2015-01-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP2862852B1
(en)
|
2013-10-18 |
2018-07-04 |
Symrise AG |
Urea derivatives for the protection of stem cells
|
KR102258645B1
(ko)
|
2013-11-05 |
2021-05-28 |
쓰리엠 이노베이티브 프로퍼티즈 캄파니 |
참기름을 베이스로 하는 주사 제제
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
KR20160095035A
(ko)
|
2013-12-06 |
2016-08-10 |
노파르티스 아게 |
알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
|
US9695171B2
(en)
|
2013-12-17 |
2017-07-04 |
Pfizer Inc. |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
|
CN114671954A
(zh)
|
2014-01-10 |
2022-06-28 |
博笛生物科技有限公司 |
靶向her2阳性肿瘤的化合物和组合物
|
WO2015108595A1
(en)
|
2014-01-15 |
2015-07-23 |
Nikolai Khodarev |
Anti-tumor therapy
|
EP2921157B1
(en)
|
2014-03-18 |
2017-08-16 |
Symrise AG |
Coated titanium dioxide to reduce whitening effect on skin
|
SG11201606887WA
(en)
|
2014-03-26 |
2016-09-29 |
Glaxosmithkline Biolog Sa |
Mutant staphylococcal antigens
|
EP2939710B1
(en)
|
2014-04-29 |
2020-06-17 |
Symrise AG |
Active Mixtures
|
WO2015171975A1
(en)
|
2014-05-09 |
2015-11-12 |
The Regents Of The University Of Michigan |
Use of modified banana lectin in purification of glycoproteins
|
US10093720B2
(en)
|
2014-06-11 |
2018-10-09 |
International Aids Vaccine Initiative |
Broadly neutralizing antibody and uses thereof
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN107074958A
(zh)
|
2014-07-09 |
2017-08-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗‑pd‑l1组合
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
FR3031105B1
(fr)
|
2014-12-31 |
2018-04-06 |
Universite De Montpellier |
Nouveaux imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers
|
EP3045161A1
(en)
|
2015-01-18 |
2016-07-20 |
Symrise AG |
Active compositions comprising 1,2-hexanediol and 1,2-octanediol
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
WO2016183371A1
(en)
|
2015-05-13 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for the treatment or prevention of ischemic tissue damage
|
CA2996213C
(en)
|
2015-08-31 |
2023-10-03 |
3M Innovative Properties Company |
Guanidine substituted imidazo[4,5-c] ring compounds
|
CN113402518B
(zh)
|
2015-08-31 |
2023-08-22 |
3M创新有限公司 |
含有取代的胍基团的咪唑并[4,5-c]环化合物
|
WO2017044803A1
(en)
|
2015-09-09 |
2017-03-16 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Service |
Expression vector delivery system and use thereof for inducing an immune response
|
JP6873980B2
(ja)
*
|
2015-09-14 |
2021-05-19 |
ファイザー・インク |
LRRK2阻害薬としての新規のイミダゾ[4,5−c]キノリンおよびイミダゾ[4,5−c][1,5]ナフチリジン誘導体
|
JP6764930B2
(ja)
|
2015-09-29 |
2020-10-07 |
大日本住友製薬株式会社 |
アデニンコンジュゲート化合物およびそのワクチンアジュバントとしての使用
|
US9925258B2
(en)
|
2015-10-02 |
2018-03-27 |
International Aids Vaccine Initiative |
Replication-competent VSV-HIV Env vaccines
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
AU2016334826B2
(en)
|
2015-10-07 |
2020-08-27 |
Sumitomo Pharma Co., Ltd. |
Pyrimidine compound
|
KR20180073674A
(ko)
|
2015-11-02 |
2018-07-02 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-her2组合
|
US11191821B2
(en)
|
2016-02-27 |
2021-12-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccine formulations and use thereof for inducing an immune response
|
US10533007B2
(en)
*
|
2016-04-19 |
2020-01-14 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
CA3023672A1
(en)
|
2016-05-16 |
2017-11-23 |
Infectious Disease Research Institute |
Pegylated liposomes and methods of use
|
JP7195148B2
(ja)
|
2016-05-16 |
2022-12-23 |
アクセス ツー アドバンスト ヘルス インスティチュート |
Tlrアゴニストを含有する製剤及び使用方法
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
CN109843327B
(zh)
|
2016-07-07 |
2022-05-13 |
小利兰·斯坦福大学托管委员会 |
抗体佐剂缀合物
|
CN109641920A
(zh)
|
2016-08-26 |
2019-04-16 |
3M创新有限公司 |
由胍基基团取代的稠合[1,2]咪唑并[4,5-c]环化合物
|
JP7240311B2
(ja)
|
2016-08-30 |
2023-03-15 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
薬物送達組成物およびその使用
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
US10941252B2
(en)
|
2016-11-03 |
2021-03-09 |
3M Innovative Properties Company |
Silicone copolymers, methods of making, and articles
|
CA3043480A1
(en)
|
2016-11-09 |
2018-05-17 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions for adaptive immune modulation
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
JP7071392B2
(ja)
|
2016-12-05 |
2022-05-18 |
アプロス セラピューティクス, インコーポレイテッド |
酸性基を含有するピリミジン化合物
|
US10766896B2
(en)
|
2017-03-01 |
2020-09-08 |
3M Innovative Properties Company |
Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups
|
EP3592741B1
(en)
*
|
2017-03-10 |
2023-02-15 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
CA3057813A1
(en)
|
2017-03-29 |
2018-10-04 |
Sumitomo Dainippon Pharma Co., Ltd. |
Vaccine adjuvant formulation
|
WO2018187515A1
(en)
|
2017-04-04 |
2018-10-11 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
DK3625231T3
(da)
*
|
2017-05-19 |
2022-10-31 |
Superb Wisdom Ltd |
Derivatives of resiquimod
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
EP3641771A4
(en)
|
2017-06-23 |
2020-12-16 |
Birdie Biopharmaceuticals, Inc. |
PHARMACEUTICAL COMPOSITIONS
|
JP7386536B2
(ja)
|
2017-08-22 |
2023-11-27 |
ダイナヴァックス テクノロジーズ コーポレイション |
アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
|
WO2019099412A1
(en)
|
2017-11-14 |
2019-05-23 |
Dynavax Technologies Corporation |
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
WO2019123178A1
(en)
|
2017-12-20 |
2019-06-27 |
3M Innovative Properties Company |
Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
EP3730152A4
(en)
|
2017-12-21 |
2022-01-12 |
Sumitomo Dainippon Pharma Co., Ltd. |
COMBINATION DRUGS WITH TLR7 AGONIST
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Il−15バリアントおよびその使用
|
EP3759107A1
(en)
*
|
2018-02-28 |
2021-01-06 |
3M Innovative Properties Company |
Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
|
US20210113705A1
(en)
|
2018-05-22 |
2021-04-22 |
Avidea Technologies, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
EP3797121B1
(en)
|
2018-05-23 |
2024-06-19 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
KR20230146098A
(ko)
|
2018-05-23 |
2023-10-18 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
US11884662B2
(en)
|
2018-05-24 |
2024-01-30 |
3M Innovative Properties Company |
N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
CA3101454A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Messenger rna vaccines and uses thereof
|
JP7351859B2
(ja)
|
2018-06-04 |
2023-09-27 |
アプロス セラピューティクス, インコーポレイテッド |
Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
|
CN112839673A
(zh)
|
2018-07-23 |
2021-05-25 |
日本国立感染症研究所所长代表之日本国 |
包含流感疫苗的组合物
|
US20210353740A1
(en)
|
2018-09-23 |
2021-11-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
|
AU2019355926A1
(en)
|
2018-10-03 |
2021-04-22 |
Barinthus Biotherapeutics North America, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
US20210323962A1
(en)
|
2018-11-26 |
2021-10-21 |
3M Innovative Properties Company |
N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
JP2022529183A
(ja)
|
2019-04-17 |
2022-06-17 |
アヴィディア テクノロジーズ, インコーポレイテッド |
リガンド提示および/または薬物送達のためのスターポリマーを製造する組成物および方法
|
WO2020245706A1
(en)
|
2019-06-06 |
2020-12-10 |
3M Innovative Properties Company |
N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
EP3983408A1
(en)
|
2019-06-12 |
2022-04-20 |
3M Innovative Properties Company |
Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
|
AU2020310853A1
(en)
|
2019-07-05 |
2022-01-27 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
WO2021116420A1
(en)
|
2019-12-13 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
|
AU2020410410A1
(en)
|
2019-12-17 |
2022-06-09 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
WO2021168318A1
(en)
|
2020-02-21 |
2021-08-26 |
International Aids Vaccine Initiative Inc. |
Vaccine compositions for preventing coronavirus disease
|
US20230165723A1
(en)
|
2020-04-30 |
2023-06-01 |
Kindeva Drug Delivery L.P. |
Adhesive article and method of making same
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
EP4182346A1
(en)
|
2020-07-17 |
2023-05-24 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
JP2023537066A
(ja)
|
2020-08-07 |
2023-08-30 |
タンボ・インコーポレイテッド |
トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
|
FR3113287B1
(fr)
|
2020-08-07 |
2023-06-23 |
Phv Pharma |
Procédé industriel de synthèse de l’imiquimod à partir de la quinolèine-2,4-diol applicable à son utilisation pharmaceutique
|
EP4216927A1
(en)
|
2020-09-22 |
2023-08-02 |
Vaccitech North America, Inc. |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
EP4228701A1
(en)
|
2020-10-19 |
2023-08-23 |
Vaccitech North America, Inc. |
Star polymer drug conjugates
|
WO2022125750A1
(en)
*
|
2020-12-09 |
2022-06-16 |
Wellstat Therapeutics Corporation |
Imidazoquinoline compound having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
|
CA3207998A1
(en)
|
2021-02-16 |
2022-08-25 |
Geoffrey M. Lynn |
Self-assembling nanoparticles based on amphiphilic peptides
|
ES2940736B2
(es)
|
2021-11-09 |
2023-09-19 |
Ntd Labs S L U |
Uso combinado de imiquimod y de un hidrolizado de caseina para el tratamiento de condilomas
|
WO2024092028A2
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Combination treatment regimes for treating cancer
|
WO2024092030A1
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Self-assembling nanoparticles
|